Abcellera Biologics Stock Buy Hold or Sell Recommendation
| ABCL Stock | USD 2.52 0.12 5.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Abcellera Biologics is 'Hold'. The recommendation algorithm takes into account all of Abcellera Biologics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Abcellera Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide. Note, we conduct extensive research on individual companies such as Abcellera and provide practical buy, sell, or hold advice based on investors' constraints. Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Abcellera |
Execute Abcellera Biologics Buy or Sell Advice
The Abcellera recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Abcellera Biologics. Macroaxis does not own or have any residual interests in Abcellera Biologics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Abcellera Biologics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Abcellera Biologics Trading Alerts and Improvement Suggestions
| Abcellera Biologics generated a negative expected return over the last 90 days | |
| Abcellera Biologics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 28.83 M. Net Loss for the year was (162.86 M) with loss before overhead, payroll, taxes, and interest of (138.43 M). | |
| Abcellera Biologics currently holds about 868.21 M in cash with (108.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Abcellera Biologics has a frail financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Thermopylae Holdings Ltd. of 343631 shares of Abcellera Biologics at 2.16 subject to Rule 16b-3 |
Abcellera Biologics Returns Distribution Density
The distribution of Abcellera Biologics' historical returns is an attempt to chart the uncertainty of Abcellera Biologics' future price movements. The chart of the probability distribution of Abcellera Biologics daily returns describes the distribution of returns around its average expected value. We use Abcellera Biologics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Abcellera Biologics returns is essential to provide solid investment advice for Abcellera Biologics.
| Mean Return | -0.16 | Value At Risk | -7.67 | Potential Upside | 5.38 | Standard Deviation | 4.49 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Abcellera Biologics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Abcellera Stock Institutional Investors
| Shares | Tang Capital Management Llc | 2024-12-31 | 2.6 M | Renaissance Technologies Corp | 2024-12-31 | 2.5 M | Ubs Group Ag | 2024-12-31 | 2 M | Guardian Partners Inc. | 2024-12-31 | 1.8 M | Guardian Capital Advisors Lp | 2024-09-30 | 1.8 M | Millennium Management Llc | 2024-12-31 | 1.5 M | Norges Bank | 2024-12-31 | 1.3 M | Novo A/s | 2024-12-31 | 1.1 M | Opaleye Management Inc | 2024-12-31 | 965 K | Baker Bros Advisors Lp | 2024-12-31 | 27.5 M | Baillie Gifford & Co Limited. | 2024-12-31 | 12.2 M |
Abcellera Biologics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (150.1K) | (134.3M) | 40.9M | 18.3M | 21.0M | 22.0M | |
| Investments | (19.2M) | (277.4M) | (352.6M) | (213.8M) | 121.4M | 127.5M | |
| Change In Cash | 586.6M | (93.0M) | (86.5M) | (254.0M) | 23.0M | 21.0M | |
| Net Borrowings | 180.7K | 85.2M | (951K) | (323K) | (290.7K) | (276.2K) | |
| Free Cash Flow | 8.0M | 186.1M | 204.7M | (121.4M) | (187.0M) | (177.6M) | |
| Depreciation | 5.3M | 17.3M | 33.1M | 30.9M | 90.8M | 95.4M | |
| Other Non Cash Items | 4.7M | 3.6M | 8.5M | (7.7M) | (104.1M) | (98.9M) | |
| Capital Expenditures | 14.7M | 58.5M | 72.7M | 77.5M | 78.4M | 48.9M | |
| Net Income | 118.9M | 153.5M | 158.5M | (146.4M) | (162.9M) | (154.7M) | |
| End Period Cash Flow | 594.1M | 501.1M | 414.7M | 160.6M | 183.6M | 294.2M | |
| Change To Netincome | 1.1M | 15.2M | 32.2M | 55.9M | 64.3M | 67.5M |
Abcellera Biologics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Abcellera Biologics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Abcellera Biologics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Abcellera stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.0057 | |
β | Beta against Dow Jones | 1.55 | |
σ | Overall volatility | 4.58 | |
Ir | Information ratio | -0.01 |
Abcellera Biologics Volatility Alert
Abcellera Biologics exhibits very low volatility with skewness of 0.17 and kurtosis of 1.38. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Abcellera Biologics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Abcellera Biologics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Abcellera Biologics Fundamentals Vs Peers
Comparing Abcellera Biologics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Abcellera Biologics' direct or indirect competition across all of the common fundamentals between Abcellera Biologics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Abcellera Biologics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Abcellera Biologics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Abcellera Biologics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Abcellera Biologics to competition |
| Fundamentals | Abcellera Biologics | Peer Average |
| Return On Equity | -0.15 | -0.31 |
| Return On Asset | -0.12 | -0.14 |
| Operating Margin | (8.07) % | (5.51) % |
| Current Valuation | 189.19 M | 16.62 B |
| Shares Outstanding | 297.99 M | 571.82 M |
| Shares Owned By Insiders | 22.88 % | 10.09 % |
| Shares Owned By Institutions | 42.46 % | 39.21 % |
| Number Of Shares Shorted | 20.1 M | 4.71 M |
| Price To Earning | 16.67 X | 28.72 X |
| Price To Book | 0.71 X | 9.51 X |
| Price To Sales | 26.04 X | 11.42 X |
| Revenue | 28.83 M | 9.43 B |
| Gross Profit | (138.43 M) | 27.38 B |
| EBITDA | (204.15 M) | 3.9 B |
| Net Income | (162.86 M) | 570.98 M |
| Cash And Equivalents | 868.21 M | 2.7 B |
| Cash Per Share | 3.04 X | 5.01 X |
| Total Debt | 60.74 M | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 9.86 X | 2.16 X |
| Book Value Per Share | 3.57 X | 1.93 K |
| Cash Flow From Operations | (108.56 M) | 971.22 M |
| Short Ratio | 4.65 X | 4.00 X |
| Earnings Per Share | (0.55) X | 3.12 X |
| Price To Earnings To Growth | 2.22 X | 4.89 X |
| Target Price | 11.86 | |
| Number Of Employees | 596 | 18.84 K |
| Beta | 0.45 | -0.15 |
| Market Capitalization | 750.93 M | 19.03 B |
| Total Asset | 1.36 B | 29.47 B |
| Retained Earnings | 116.93 M | 9.33 B |
| Working Capital | 674.76 M | 1.48 B |
| Net Asset | 1.36 B |
Note: Acquisition by Lo Andrew of 91325 shares of Abcellera Biologics at 14.02 subject to Rule 16b-3 [view details]
Abcellera Biologics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Abcellera . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Abcellera Biologics Buy or Sell Advice
When is the right time to buy or sell Abcellera Biologics? Buying financial instruments such as Abcellera Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Abcellera Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Abcellera Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.55) | Revenue Per Share | Quarterly Revenue Growth (0.45) | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.